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Background: Tumor necrosis factor alpha (TNF-α) plays an important role in inflammation, immunity, and defense
against infection and clearance of human papillomavirus (HPV). Thus, genetic variants may modulate individual
susceptibility to HPV-associated oral squamous cell carcinoma (OSCC).
Methods: In this study we genotyped four common single nucleotide polymorphisms (SNPs) in the TNF-α
promoter [ −308G > A(rs1800629), -857C > T (rs1799724), -863C > A (rs1800630), and -1031T > C (rs1799964)] and
determined HPV16 serology in 325 OSCC cases and 335 matched controls and tumor HPV status in 176 squamous
cell carcinomas of the oropharynx (SCCOP) patients. Univariate and multivariable logistic regression models were
used to calculate odds ratios (ORs) and 95% confidence intervals (CIs).
Results: We found that HPV16 seropositivity alone was associated with an increased risk of OSCC (OR, 3.1; 95% CI,
2.1–4.6), and such risk of HPV16-associated OSCC was modified by each SNP. Patients with both HPV16
seropositivity and variant genotypes for each SNP had the highest risk when using patients with HPV16
seronegativity and a wild-type genotype as a comparison group. Moreover, similar results were observed for the
combined risk genotypes of four variants and all such significant associations were more pronounced in several
subgroups, particularly in SCCOP patients and never smokers. Notably, the combined risk genotypes of four variants
were also significantly associated with tumor HPV-positive SCCOP.
Conclusion: Taken together, these results suggest that TNF-α SNPs may individually or, more likely, jointly affect
individual susceptibility to HPV16-associated OSCC, particularly SCCOP and never smokers. Validation of our findings
is warranted.
Keywords: TNF-α, Polymorphism, HPV infection, Oropharyngeal cancer, Case–control studyIntroduction
Oral squamous cell carcinoma (OSCC) includes cancers
arising from the oropharynx and oral cavity. In the
United States, an estimated 40 250 new cases of OSCC
and 7850 deaths from OSCC are expected in 2012 [1].
Tobacco and alcohol are well-established risk factors for* Correspondence: gli@mdanderson.org
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reproduction in any medium, provided the orOSCC. Corresponding with the decrease in tobacco use
in the United States, the incidence rate of OSCC has de-
clined in the past two decades, while the incidence of a
subgroup of OSCC, squamous cell carcinomas of the
oropharynx (SCCOP), has increased in recent years, par-
ticularly in young adults and nonsmokers and non-
drinkers. The rising incidence of SCCOP in the United
States is likely a consequence of persistent infection with
human papillomavirus (HPV), predominantly high-risk
HPV type 16 (HPV16). The overall rise in SCCOP inci-
dence during 1984 to 2004 is largely explained by the
increasing incidence of HPV-positive cancers, whereas
incidence of HPV-negative cancers declined. Consequently,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stantially from 16.3% during the 1980s to 72.7% during the
2000s [2-4]. Population-level incidence of HPV-positive
SCCOP increased by 225% from 1988 to 2004 (from 0.8
per 100,000 to 2.6 per 100,000), while the incidence for
HPV-negative SCCOP decreased by 50% (from 2.0 per
100,000 to 1.0 per 100,000) [2]. In addition to HPV infec-
tion, it is likely that other, as-yet-unknown genetic factors
in inflammation and immune response pathways may also
be associated with the risk of HPV-associated OSCC, par-
ticularly SCCOP.
The host immune responses and chronic inflammation
have been shown to be biologically important risk fac-
tors for HPV-related carcinogenesis, and increased dur-
ation of persistent HPV infection may be influential in
determining disease development, indicating the impor-
tance of the host immune response to HPV clearance
and HPV-related carcinogenesis. Cytokines are a group
of host immune products involved in inflammation, im-
munity, defense against HPV infection, and modulation
of HPV clearance. Tumor necrosis factor-alpha (TNF-α)
is a multifunctional cytokine in the host response to in-
flammation, immunity, and the defense against viral in-
fections [5]. TNF-α may be involved in carcinogenesis
through induction of proliferation, invasion, and metas-
tasis because it may have both tumor-necrotic and
tumor-promoting activities [6]. Increased expression of
TNF-α has been observed in association with HPV infec-
tion in both normal cervical tissues and cervical cancers
[7], supporting the importance of TNF-α in response to
HPV and to subsequent carcinogenesis. TNF-α also has
been found to repress expression of oncogenes E6 and E7
at the translation level in HPV16-immortalized human
cells [8], induces apoptosis and growth arrest in normal
and HPV16-infected cells [9,10], and stimulates inflamma-
tory response through upregulation of chemokines and
other inflammatory regulators [8,11]. On the other hand,
HPV16 could modulate the effect of TNF-α because
E6 and E7 expressions are associated with resistance to
the TNF-α-mediated apoptosis and TNF-α-induced anti-
proliferative effect, suggesting an important role for TNF-
α in HPV-associated carcinogenesis [9,12]. In contrast,
TNF-α also promotes tumor activity by stimulating the
proliferation of cervical cells immortalized and transformed
by HPV [13,14]. Therefore, TNF-α expression levels may
influence HPV infection and subsequent HPV-associated
cancer development.
Given the potential roles of TNF-α as an important
and pleiotropic cytokine that plays a critical role in im-
mune regulation through prominent anti-inflammatory
and immunoregulatory activities (11), its genetic variants
may affect the host immune system and HPV infection
and, subsequently, the HPV-associated cancer develop-
ment. Several single nucleotide polymorphisms (SNPs)in the promoter region of the TNF-α gene may have pu-
tatively functional changes and thus may affect an indi-
vidual’s susceptibility to cancer. For example, the SNP at
site −308 (G➔A, rs1800629) was shown to affect the
transcriptional activity of TNF-α because that SNP’s A allele
was associated with increased TNF-α production in vitro
[15]. In addition, an enhanced transcriptional activity was
associated with the minor alleles of SNPs at −857 (C➔T,
rs1799724), -863 (C➔A, rs1800630), and −1031 (T➔C,
rs1799964) in response to stimuli [16]. Therefore, we hy-
pothesized that these promoter SNPs may be associated
with risk of HPV-associated OSCC, particularly SCCOP.
Several studies have evaluated associations of the above-
mentioned TNF-α promoter SNPs with the risk of several
types of cancer, including those of the cervix, stomach, and
colon and rectum and non-Hodgkin lymphoma [17-20].
Studies on associations between TNF-α variants at −308
and −1031 and risk of oral cancer also been reported, but
the results between those studies were not consistent and
those studies also had relatively small sample sizes [20-26].
More importantly, studies specifically evaluating the
effect of TNF-α promoter SNPs on the risk of HPV-
associated OSCC are lacking. Therefore, in the present
study, we genotyped TNF-α promoter SNPs [−308G > A
(rs1800629), -857C >T (rs1799724), -863C >A (rs1800630),
and -1031T >C (rs1799964)] and evaluated their associa-
tions with risk of HPV16-associated OSCC in 325 OSCC




In this case–control study, the 325 cases were patients
with newly diagnosed, histopathologically confirmed and
untreated OSCC. The details of recruitment and the in-
clusion criteria for these cases were described previously
[27]. Briefly, these cases had been consecutively recruited
during the period between May 1996 and May 2002 at
The University of Texas MD Anderson Cancer Center as
part of an ongoing molecular epidemiologic study of head
and neck cancers. During that same period, the controls
had been selected from a pool of cancer-free subjects
recruited from the Kelsey-Seybold Foundation, a multi-
specialty physician practice with multiple clinics through-
out the Houston metropolitan area, as well as from healthy
visitors who had accompanied cancer patients to outpatient
clinics at MD Anderson but who were genetically unrelated
to the patients. The 335 controls were frequency-matched
to the patients by age (±5 years), sex, and smoking and
drinking status. Only non-Hispanic whites were included as
controls because most of the cancer patients recruited were
non-Hispanic whites. Approximately 95% of eligible inci-
dent cases and 78% of eligible controls had agreed to par-
ticipate in the study. The study received approval from
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and Kelsey-Seybold, and all study subjects signed an in-
formed consent when approached for recruitment. Sub-
jects who had smoked more than 100 cigarettes in their
lifetimes were categorized as “ever-smokers,” and others
as “never-smokers.” Subjects who had consumed alco-
holic beverages at least once a week for more than 1
year previously were categorized as “ever-drinkers,” and
others as “never-drinkers”.
HPV16 serological testing
For the current study, serum samples from each subject
were tested for anti-HPV16 (antibody against HPV16)
by a standard enzyme-linked immunosorbent assay with
HPV16 L1 virus-like particles generated from recombinant
baculovirus-infected insect cells, as described previously
[28]. Ten percent of the samples were randomly chosen for
re-testing, and the results were in 100% concordance with
those of the initial assays.
Tumor HPV16 determination
Paraffin-embedded tissues were tested for HPV16 DNA
using polymerase chain reaction (PCR)-based, type-specific
assays with modification and quality control for the E6 and
E7 regions [3,4]. Assays of the samples were run in tripli-
cate, with positive and negative controls (Siha and TPC-1
cell lines, respectively). β-actin was used as a DNA quality
control. Specificity for HPV16 E6 and E7 was confirmed by
Southern blot analysis of paraffin-embedded tissue samples
using a Roche Diagnostics labeling and hybridization sys-
tem (Roche Applied Science, Indianapolis, IN) [4]. HPV16
E6 and E7 specificity was confirmed by retesting 10% of
the samples using restriction digestion of the PCR products
with BanII and MspI to verify the presence of E6- and E7-
specific fragments. The results of both methods were 100%
concordant.
TNF-α genotyping
For this study, we extracted genomic DNA from a leu-
kocyte cell pellet using the QIAamp DNA Blood Mini KitTable 1 Summary of TNF-α PCR-RFLP analysis
Variants Primer sequence (5′ to 3′) PCR
productsUpper-forward; lower-reverse
NF-α-308G > A (rs1800629) AGGCAATAGCTTTTGAGGGCCATG 80 bp
TCTTCTGGGCCACTGACTGAT
TNF-α-857C > T (rs1799724) CGAGTATGGGGACCCTCCCATTAA 100 bp
ACGTCCCCTGTATTCCATACC
TNF-α-863C > A (rs1800630) GACCACAGCAATGGGTAGGAGA 86 bp
TCTACATGGCCCTGTCCTCGT
TNF-α-1031T > C (rs1799964) AGAGCTGTGGGGAGAACAAA 247 bp
CTCCTACCCATTGCTGTGGT(QIAGEN Inc., Valencia, CA) in accordance with the man-
ufacturer’s instructions. The polymerase chain reaction-
restriction fragment length polymorphisms (PCR-RFLP)
method was used for genotyping the selected SNPs. Infor-
mation on primers and endonucleases used are provided
in Table 1. Genotyping was performed by laboratory per-
sonnel blinded to the case–control status. Repeated analysis
was performed on a randomly selected subset of 10% of the
samples, and the results were in 100% concordance with
the initial analysis.Statistical analysis
Statistical analyses were performed using the SAS soft-
ware, version 9.2 (SAS Institute Inc., Cary, NC). All tests
were two-sided, and a P value of < 0.05 was considered
the cutoff for statistical significance. We used χ2 tests to
examine differences between the patients and controls in
the distributions of demographic variables, smoking sta-
tus, drinking status, HPV16 status, and genotypes. We
evaluated both the association of HPV16 status and
TNF-α genotypes, individually and in combination, with
the risk of OSCC by computing odds ratios (OR) and
their 95% confidence intervals (CI), using both univari-
ate and multivariable logistic regression analyses. The
analyses of joint effects were further stratified by tumor
site and patient age and smoking and drinking status.Results
Demographics and risk factors for the study population
The demographics and OSCC risk factors for the 325
patients and 335 controls are shown in Table 2. Among
the 325 patients, 188 (57.8%) had SCCOP, and 137 (42.2%)
had oral cavity cancers. Age, sex, and smoking and drink-
ing status did not differ significantly between patients
and controls as a result of frequency matching. However,
HPV16 seropositivity was more common in patients than
in controls (P < 0.001) and was associated with a 3.1-times
higher risk of OSCC than in controls (OR, 3.1; 95% CI,
2.1–4.6).Anneal T Allele
(°C) Enzymes used determination
60 Sty I Intact :-308GG
58 bp + 22 bp :-308GA + AA
57 Ase1 Intact :-857CC
78 bp + 22 bp :-857CT + TT
60 Bsl I Intact :-863CC
64 bp + 22 bp :-863CA + AA
62 Bbs I Intact :-1031TT
127 bp + 120 bp :-1031TC + CC
Table 2 Demographic and risk factors in patients and
controls and their association with risk of OSCC
Variables Patients (n = 325) Controls (n = 335)*
No. % No. %
Age (years)
≤ 40 31 9.5 27 8.1
41 – 55 126 38.8 105 31.3
56 – 70 119 36.7 154 46.0
> 70 49 15.0 49 14.6
Sex
Male 241 74.2 269 80.3
Female 84 25.8 66 19.7
Tobacco smoking
Ever 227 69.8 239 71.3
Never 98 30.2 96 28.7
Alcohol drinking
Ever 250 76.9 240 71.6
Never 75 23.1 95 28.4
HPV16 serologya
Negative 225 69.2 293 87.5
Positive 100 30.8 42 12.5
*The cases and controls were adequately frequency-matched.
asignificantly different in HPV16 serological status between cases and controls.
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the risk of OSCC
Table 3 shows the association between TNF-α genetic
variants and the risk of HPV16-associated OSCC. Corre-
sponding to each SNP, HPV16-seropositive individuals
carrying variant genotypes of TNF-α-308A, TNF-α-857T,
TNF-α-863A, or TNF-α-1031C had a higher risk of OSCC
after adjustment for age, sex, and smoking and drinking
status than did individuals with both HPV16-seronegativity
and the homozygous wild-type genotype. For each SNP,
using individuals with both HPV16 seronegativity and the
homozygous wild-type genotype as the reference group,
the risk of OSCC increased among individuals with both
variant genotypes and HPV16 seronegativity, both wild-
type genotype and HPV16 seropositivity, and both variant
genotypes and HPV16 seropositivity, respectively. For ex-
ample, compared with individuals with the TNF-α-308 GG
genotype and HPV16 seronegativity, the risk increased
among those with GA or AA genotypes and HPV16 sero-
negativity (OR, 1.3; 95% CI, 1.0–1.9), GG genotype and
HPV16 seropositivity (OR, 2.5; 95% CI, 1.3–4.8), and GA
or AA genotypes and HPV16 seropositivity (OR, 4.8; 95%
CI, 2.7–8.4). The similar results were found for other SNPs
(Table 3). Furthermore, all such significant associations
were particularly evident for SCCOP as opposed to oral
cavity cancers.To assess the combined effect of TNF-α SNPs on the
risk of HPV16-associated OSCC, individuals were fur-
ther categorized into three groups according to their
number of risk genotypes on the basis of results of
OSCC risk associated with each individual SNP: 1) a
low-risk group (individuals carrying 0–1 risk genotypes);
2) a medium-risk group (individuals carrying 2 risk ge-
notypes); and 3) a high-risk group (individuals carrying 3
or 4 risk genotypes) as shown in Table 4. When we used
HPV16-seronegative individuals from the low-risk group
as the reference group, we found that the risk of OSCC
significantly increased among HPV16-seronegative indi-
viduals categorized as high-risk (OR, 1.8; 95% CI, 1.1–
2.8), among HPV16-seropositive individuals categorized
as low-risk (OR, 1.5; 95% CI, 1.0–2.9), among HPV16-
seropositive individuals categorized as medium-risk (OR,
2.7; 95% CI, 1.3–5.8), and among HPV16-seropositive
individuals categorized as high-risk (OR, 8.5; 95% CI,
3.7–19.4). The exception was HPV16-seronegative indi-
viduals from the medium-risk group (OR, 1.0; 95% CI,
0.3–1.0). Again, all aforementioned associations were
particularly pronounced for SCCOP as opposed to oral
cavity cancers.
Stratification analysis of the joint effect of HPV16
serology and combined risk genotypes of TNF-α on risk
of OSCC
We further evaluated the association between the com-
bined risk genotypes of TNF-α and risk of HPV16-
associated OSCC stratified by age and smoking status.
As shown in Table 5, the joint effect of both HPV16 ser-
ology and combined risk genotypes of TNF-α on risk of
OSCC was greater in young (less than 50 years old) sub-
jects than in subjects older than 50 years or older. Spe-
cifically, a 22.6-times higher risk of OSCC was found in
HPV16-seropositive young subjects in the high-risk
genotype group, compared with a 5.7-times higher risk
of OSCC in HPV16-seropositive older subjects in the
high-risk group. Similarly, as shown in Table 6, never-
smokers were at greater risk of OSCC than were ever-
smokers, respectively. Specifically, HPV16-seropositive
individuals in the high-risk genotype group had an OR
of 35.6 in never-smokers versus an OR of 4.8 in ever-
smokers. Moreover, such risk estimates stratified by age
and smoking status were even more pronounced for
SCCOP (Tables 5 and 6), whereas we did not observe
similar associations among patients with oral cavity can-
cers (data not shown).
Association of combined risk genotypes of four TNF-α
SNPs with tumor HPV16-positive SCCOP
To further confirm the modifying effects of TNF-α pro-
moter variant on risk of HPV16-associated SCCOP, we
assessed the association of the combined risk genotypes
Table 3 Associations of TNF-α SNPs with risk of HPV16-associated OSCC
Patients Controls Adjusted OR (95% CI)1
(n = 325) (n = 335)
Variables HPV16 Status No. % No. % OSCC SCCOP Oral cavity
TNF-α-308
GG − 70 21.5 109 32.5 1.0 1.0 1.0
GA + AA − 155 47.7 184 54.9 1.3 (1.0 − 1.9) 1.4 (1.0 − 2.3) 0.4 (0.1 − 1.5)
GG + 31 9.5 19 5.7 2.5 (1.3 − 4.8) 4.6 (2.2 − 9.5) 1.1 (0.7 − 1.8)
GA + AA + 69 21.2 23 6.9 4.8 (2.7 − 8.4) 9.3 (4.9 − 17.6) 1.2 (0.5 − 2.8)
TNF-α-857
CC − 198 60.9 261 77.9 1.0 1.0 1.0
CT + TT − 27 8.3 32 9.6 1.2 (0.7 − 2.1) 1.4 (0.7 − 2.7) 0.7 (0.3 − 1.4)
CC + 85 26.2 38 11.3 3.0 (2.0 − 4.7) 5.6 (3.5 − 9.0) 1.0 (0.5 − 1.9)
CT + TT + 15 4.6 4 1.2 5.3 (1.7 − 16.2) 9.3 (3.0 − 29.6) 1.5 (0.3 − 8.6)
TNF-α-863
CC − 66 20.31 115 34.3 1.0 1.0 1.0
CA + AA − 159 48.9 178 53.1 1.6 (1.1 − 2.3) 1.8 (0.8 − 2.2) 0.8 (0.3 − 2.4)
CC + 34 10.5 19 5.7 3.1 (1.6 − 5.9) 5.2 (2.5 − 10.5) 1.7 (1.0 − 2.7)
CA + AA + 66 20.3 23 6.9 5.3 (3.0 − 9.4) 8.5 (4.6 − 16.0) 1.3 (0.5 − 3.2)
TNF-α-1031
TT − 71 21.9 115 34.3 1.0 1.0 1.0
TC + CC − 154 47.4 178 53.1 1.4 (1.0 − 2.0) 1.6 (1.0 − 2.6) 0.7 (0.2 − 2.3)
TT + 31 9.5 17 5.1 3.1 (1.6 − 6.1) 6.0 (2.8 − 12.4) 1.2 (0.8 − 2.0)
TC + CC + 69 21.2 25 7.5 4.5 (2.6 − 7.9) 9.0 (4.8 − 16.7) 1.0 (0.4 − 2.3)
1Adjusted for age, sex, and smoking and alcohol drinking status.
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HPV16 status instead of HPV16 serology. Of 188 SCCOP
patients, we determined the tumor HPV16 status among
176 SCCOP patients whose specimens were available for
such a testing. We found that the combined genotypes of
four variants were significantly associated with tumor
HPV16-positive SCCOP patients, and the patients in




(n = 325) (n = 3
No. % No.
Low-risk group − 61 18.8 81
Medium-risk group − 53 16.3 129
High-risk group − 111 34.2 83
Low-risk group + 27 8.3 13
Medium-risk group + 23 7.1 21
High-risk group + 50 15.4 8
1Low-risk group: individuals carrying 0–1 risk genotypes; medium-risk group: individ
risk genotypes.
2Adjusted for age, sex, and smoking and alcohol drinking status.HPV16-positive SCCOP compared with those in low-risk
group (OR, 5.4; 95% CI, 2.5-11.7) (Table 7).
Discussion
The results of this study show that TNF-α variants may
individually or, more likely, jointly modulate the risk of
HPV16-associated OSCC, particularly for SCCOP, and
that the joint effect of combined risk genotypes andgenotypes of TNF-α SNPs on risk of OSCC
ols Adjusted OR (95% CI)2
35)
% OSCC SCCOP Oral cavity
24.2 1.0 1.0 1.0
38.5 1.0 (0.3 − 1.0) 1.0 (0.3 − 1.1) 0.5 (0.3 − 1.0)
24.8 1.8 (1.1 − 2.8) 1.8 (1.0 − 3.3) 1.6 (0.9 − 2.8)
3.9 1.5 (1.0 − 2.9) 2.9 (1.4 − 6.2) 0.7 (0.2 − 2.4)
6.3 2.7 (1.3 − 5.8) 4.9 (2.2 − 11.2) 0.2 (0.0 − 1.0)
2.4 8.5 (3.7 − 19.4) 15.8 (6.5 − 38.0) 2.3 (0.7 − 6.9)
uals carrying 2 risk genotypes; and high-risk group: individuals carrying 3 or 4
Table 5 Joint effect of HPV16 serology and the combined risk genotypes of TNF-α SNPs on risk of OSCC, stratified by age
Risk groups1 HPV16 status Patients Controls Adjusted OR (95% CI)2
(n = 325) (n = 335)
No. % No. % OSCC SCCOP
Young (aged < 50 years) (n = 87) (n = 87)
Low-risk group − 12 13.8 29 33.3 1.0 1.0
Medium-risk group − 19 21.8 35 40.2 1.2 (0.5 − 3.1) 1.1 (0.3 − 4.5)
High-risk group − 24 27.6 13 14.9 4.1 (1.5 − 11.5) 5.5 (1.4 − 21.2)
Low-risk group + 7 8.1 5 5.8 4.7 (1.1 − 19.7) 10.1 (2.0 − 52.3)
Medium-risk group + 9 10.3 3 3.5 8.9 (1.8 − 43.5) 16.6 (2.9 − 6.1)
High-risk group + 16 18.4 2 2.3 22.6 (4.2 − 121.3) 50.7 (7.5 − 341.9)
Older (aged≥ 50 years) (n = 238) (n = 248)
Low-risk group − 49 20.6 52 21.0 1.0 1.0
Medium-risk group − 34 14.3 94 37.9 0.4 (0.2 − 0.7) 0.4 (0.2 − 0.8)
High-risk group − 87 36.6 70 28.2 1.3 (0.8 − 2.2) 1.2 (0.6 − 2.3)
Low-risk group + 20 8.4 8 3.2 2.5 (1.0 − 6.2) 3.9 (1.4 − 10.6)
Medium-risk group + 14 5.9 18 7.3 0.9 (0.4 − 1.9) 1.6 (0.6 − 3.9)
High-risk group + 34 14.3 6 2.4 5.7 (2.2 − 15.0) 10.2 (3.6 − 28.4)
1Low-risk group: individuals carrying 0–1 risk genotypes; medium-risk group: individuals carrying 2 risk genotypes; and high-risk group: individuals carrying 3 or 4
risk genotypes.
2 Adjusted for age, sex, and smoking and drinking status.
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subjects and never-smokers. Moreover, the patients with
the combined risk genotypes were more likely to have
tumor HPV-positive SCCOP. These results suggest that
TNF-α SNPs may serve as a susceptibility biomarker for
HPV16-associated OSCC, especially SCCOP.Table 6 Joint effect of HPV16 serology and combined risk geno
Risk groups1 HPV16 status Patients
(n = 325)
No. %
Never-smokers (n = 99)
Low-risk group − 15 15.2
Medium-risk group − 17 17.2
High-risk group − 21 21.2
Low-risk group + 10 10.1
Medium-risk group + 11 11.1
High-risk group + 25 25.3
Ever-smokers (n = 226)
Low-risk group − 46 20.4
Medium-risk group − 36 15.9
High-risk group − 90 39.8
Low-risk group + 17 7.5
Medium-risk group + 12 5.3
High-risk group + 25 11.1
1Low-risk group: individuals carrying 0–1 risk genotypes; medium-risk group: individ
risk genotypes.
2Adjusted for age, sex, and smoking and drinking status.The four TNF-α promoter SNPs were selected for this
study because of their putatively functional potential in
affecting TNF-α production [15,16]; of which TNF-α -
308G > A has been studied mostly in association with
OSCC risk. Consistent with our results, several previous
studies found a significant increase in risk associatedtypes of TNF-α SNPs on risk of OSCC, stratified by smoking
Controls Adj. OR (95% CI)2
(n = 335)
No. % OSCC SCCOP
(n = 96)
32 33.3 1.0 1.0
38 39.6 1.0 (0.4 − 2.3) 1.0 (0.2 − 3.1)
18 18.8 2.3 (1.0 − 5.9) 2.5 (1.0 − 8.6)
5 5.2 5.4 (1.5 − 19.4) 11.0 (2.6 − 46.8)
1 1.0 28.4 (3.2 − 250.2) 51.6 (5.4 − 496.8)
1 2.1 35.6 (7.0 − 180.3) 67.4 (12.0 − 378.5)
(n = 239)
49 20.5 1.0 1.0
91 38.1 0.4 (0.2 − 0.7) 0.5 (0.2 − 1.0)
65 27.2 1.5 (0.9 − 2.6) 1.5 (0.8 − 2.9)
8 3.4 2.2 (0.8 − 5.6) 3.6 (1.3 − 10.0)
20 8.4 0.7 (0.3 − 1.5) 1.2 (0.5 − 3.1)
6 2.5 4.8 (1.8 − 12.9) 7.4 (2.6 − 21.4)
uals carrying 2 risk genotypes; and high-risk group: individuals carrying 3 or 4
Table 7 Association of the combined risk genotypes of TNF-α SNPs with tumor HPV16-positive SCCOP patients
Risk groups1 HPV-positive cases HPV-negative cases Adjusted
OR (95% CI)2(n = 107) (n = 69)
No. % No. %
Low-risk group 18 16.8 32 46.4 1.0
Medium-risk group 25 23.4 16 23.2 2.7 (1.1-6.4)
High-risk group 64 59.8 21 30.4 5.4 (2.5-11.7)
1Low-risk group: individuals carrying 0–1 risk genotypes; medium-risk group: individuals carrying 2 risk genotypes; and high-risk group: individuals carrying 3 or 4
risk genotypes.
2Adjusted for age, sex, and smoking and alcohol drinking status.
Jin et al. Molecular Cancer 2013, 12:80 Page 7 of 9
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other studies reported a significantly decreased risk asso-
ciated with the minor allele [20,26]. Along with the small
number of subjects included, differences in ethnicity
with different environmental backgrounds may account
for the inconsistencies in the findings from these studies.
For example, the two studies that reported a decreased
risk of OSCC were conducted in the East Asian region,
where chewing betel quids, smoking, and drinking are
still the predominant risk factors for OSCC [20,26].
None of these published studies has examined the as-
sociation in the context of HPV infection. For HPV-
associated cancer, several studies have reported that the
minor A allele of SNP-308 represents an increased risk
of HPV infection and HPV-associated cervical cancer from
various ethnic groups [17,29]. A meta-analysis based on
2298 cases of cervical cancer and 1903 controls from eight
study populations showed a summary OR of 1.31 (95% CI,
1.14–1.52); that analysis compared individuals carrying
the GA/AA genotypes with those carrying the GG geno-
type of TNF-α-308, in which further stratification analysis
by ethnicity showed that the risk remained significant
among both Caucasians and Asians [30].
In the present study, we showed that the risk of HPV16-
associated OSCC was modified by each of the selected
TNF-α SNPs and that a greater OR for the combined risk
genotypes suggests a joint effect of TNF-α SNPs and
HPV16 seropositivity on risk of OSCC, particularly SCCOP.
More specifically, head and neck cancer risk associated with
smoking, alcohol drinking, and HPV16 infection has been
shown to differ by tumor sites, with HPV16 infection being
the strongest risk factor for SCCOP and smoking and
drinking being the strongest risk factors for oral cavity can-
cers [31]. These findings are also in accordance with our
findings in the present study that the joint effect of HPV16
infection and TNF-α SNPs was particularly pronounced for
SCCOP as opposed to oral cavity cancers. Moreover, such a
joint effect was more evident in never-smokers. These re-
sults suggest that smoking may not play a major role in
HPV-associated OSCC, which may instead be modulated
by genetic factors such as TNF-α SNPs. This hypothesis is
further supported by the evidence that HPV16 is an inde-
pendent risk factor for SCCOP regardless of smoking ordrinking status [31]. In addition, we found a greater modify-
ing effect of TNF-α SNPs on HPV-associated OSCC in
young subjects than in older subjects, suggesting an early-
age onset of HPV-associated OSCC, a theory that not only
supports inherited susceptibility to OSCC but also is con-
sistent with the increasing prevalence of oral HPV in young
populations. In general, these results may indicate a poten-
tial interaction between TNF-α SNPs and HPV16 infection
that increases the risk of OSCC, although this hypothesis
needs to be evaluated in future studies with larger sample
sizes. In the current study, although we matched the cases
and controls by smoking status, it was necessary to further
adjust for these risk factors for their residual effect to re-
duce the bias in the estimates of the association between
TNF-α SNPs and HPV16-associated OSCC.
The combination of HPV16 infection and carrying three
or four risk genotypes of TNF-α was found in 15.4% of
OSCC patients but only in 2.4% of controls. We estimated
that individuals who have both factors had 8.5-times greater
risk of OSCC compared with HPV16-seronegative individ-
uals categorized as low-risk. Such a cumulative effect is
even more evident for SCCOP (OR, 15.8), especially in
never-smokers (OR, 67.4). Furthermore, due to the dis-
cordance between HPV serological and tumor status, we
determined the tumor HPV16 status for SCCOP patients
to further explore the association between these TNF-α
promoter variants and susceptibility to HPV-associated
SCCOP. We found that the combined risk genotypes were
also significantly associated with tumor HPV16-positive
SCCOP, indicating that the combined risk genotypes of
TNF-α SNPs may contribute to HPV16-assoctaed SCCOP.
It may be possible to use both factors in combination to as-
sess risk for individuals, especially those who never smoked,
but larger studies are needed to validate our results.
The current study had some limitations. First, there is
possible selection bias from this current case–control
study owing to the nature of its hospital-based design.
Second, since we only included non-Hispanic whites in
the study, our results cannot be generalized to other ethnic
groups. Since there were only limited numbers in some
subgroups in our stratification analysis, the results need to
be confirmed in future studies with larger sample sizes. In
addition, it is possible that HPV tumor status among study
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owing to the use of HPV serology. However, in the present
study, we took advantage of using HPV serology data for a
possible case–control study design to include HPV infor-
mation for risk evaluation, and further confirmed the asso-
ciation in a subgroup of SCCOP patients with tumor
specimens available. Nevertheless, since HPV serological
status might not fully reflect actual HPV tumor status, fu-
ture studies will be needed to establish the correlation of
HPV status between sera and tumor tissues. Finally, as we
observed, some of the confidence intervals were very wide,
indicating lack of precision and a reduced study power
owing to the small numbers of the subgroups. This can be
improved by a future patient cohort with a larger sample
size and tumor HPV information.
We conclude that the variant genotypes of TNF-α SNPs -
308G >A, -857C >T, -863C >A, and -1031T >C may be
individually or, more likely jointly, associated with risk of
HPV16-associated OSCC, particularly SCCOP, in a non-
Hispanic white population. Furthermore, we found that the
joint effects were greater among younger individuals and
never-smokers. To our knowledge, this is the first study in-
vestigating the association of TNF-α SNPs in promoter re-
gion with risk of HPV16-associated OSCC. Future studies
with larger sample sizes and more accurate HPV tumor sta-
tus information are needed to validate these findings.
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